Skip to main content
RAPT
NASDAQ Life Sciences

RAPT Therapeutics to be Acquired by GSK for $2.2 Billion in All-Cash Tender Offer at $58.00 Per Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$57.45
Mkt Cap
$972.652M
52W Low
$5.665
52W High
$42.392
52W Position info
914% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

RAPT has more than doubled off its 52-week low of $5.665.

Summary

RAPT Therapeutics has agreed to be acquired by GlaxoSmithKline for approximately $2.2 billion, with shareholders receiving $58.00 per share in cash, representing a significant premium.


Key Events · M&A and Partnerships · RAPT

  • Acquisition Agreement

    RAPT Therapeutics has entered into a definitive agreement to be acquired by GlaxoSmithKline LLC (GSK) for approximately $2.2 billion.

  • Tender Offer Price

    GSK will commence a tender offer to purchase all outstanding shares of RAPT common stock at a price of $58.00 per share in cash.

  • Significant Premium

    The offer price represents a 65% premium to the last closing price (January 16, 2026) and a 37% premium to the 52-week high of RAPT shares.

  • Strategic Rationale

    The acquisition is expected to accelerate the development of RAPT's programs, particularly ozureprubart in food allergy, leveraging GSK's global resources.


Analysis · RAPT · Life Sciences

The definitive agreement for GlaxoSmithKline to acquire RAPT Therapeutics at a substantial premium fundamentally alters the investment thesis, providing immediate and significant value to shareholders. The $2.2 billion all-cash deal represents a 65% premium over RAPT's last closing price and a 37% premium over its 52-week high, reflecting strong confidence in RAPT's pipeline, particularly ozureprubart. This strategic acquisition by a major pharmaceutical company ensures RAPT's programs will benefit from extensive resources and infrastructure, de-risking future development and commercialization. Investors should expect the stock price to converge towards the $58.00 offer price, with the transaction anticipated to close in the first quarter of 2026.

At the time of this filing, RAPT was trading at $57.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $972.7M. The 52-week trading range was $5.67 to $42.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RAPT - Latest Insights

RAPT
Mar 03, 2026, 9:02 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Mar 03, 2026, 6:05 AM EST
Filing Type: SC 14D9/A
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Mar 03, 2026, 6:04 AM EST
Filing Type: SC TO-T/A
Importance Score:
10
Price at Filing: $58.00
Real-time Price: $58.00 info
Change: $0 (0%) info
Market Cap: $1.608B info
RAPT
Feb 24, 2026, 6:08 AM EST
Filing Type: SC TO-T/A
Importance Score:
8
Price at Filing: $57.98
Real-time Price: $58.00 info
Change: +$0.020 (+0.03%) info
Market Cap: $1.608B info
RAPT
Feb 24, 2026, 6:01 AM EST
Filing Type: SC 14D9/A
Importance Score:
8
Price at Filing: $57.98
Real-time Price: $58.00 info
Change: +$0.020 (+0.03%) info
Market Cap: $1.608B info